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Abstract
Background: Glioblastoma Multiforme (GBM) is the most common and invasive astrocytic tumor associated with
dismal prognosis. Treatment for GBM patients has advanced, but the median survival remains a meager 15 months.
In a recent study, 20,000 genes from 21 GBM patients were sequenced that identified frequent mutations in ion
channel genes. The goal of this study was to determine whether ion channel mutations have a role in disease
progression and whether molecular targeting of ion channels is a promising therapeutic strategy for GBM patients.
Therefore, we compared GBM patient survival on the basis of presence or absence of mutations in calcium,
potassium and sodium ion transport genes. Cardiac glycosides, known sodium channel inhibitors, were then tested
for their ability to inhibit GBM cell proliferation.
Results: Nearly 90% of patients showed at least one mutation in ion transport genes. GBM patients with mutations
in sodium channels showed a significantly shorter survival compared to patients with no sodium channel
mutations, whereas a similar comparison based on mutational status of calcium or potassium ion channel
mutations showed no survival differences. Experimentally, targeting GBM cells with cardiac glycosides such as
digoxin and ouabain demonstrated preferential cytotoxicity against U-87 and D54 GBM cells compared to non-
tumor astrocytes (NTAs).
Conclusions: These pilot studies of GBM patients with sodium channel mutations indicate an association with a
more aggressive disease and significantly shorter survival. Moreover, inhibition of GBM cells by ion channel
inhibitors such as cardiac glycosides suggest a therapeutic strategy with relatively safe drugs for targeting GBM ion
channel mutations. Key Words: glioblastoma multiforme, ion channels, mutations, small molecule inhibitors,
cardiac glycosides.
Background
Glioblastoma multiforme (GBM) is a malignant astrocy-
tic brain tumor with a current median survival of about
15 months [1]. The current standard of care therapy is
surgery followed by concurrent radiation plus temozolo-
mide. The addition of the DNA alkylating agent temo-
zolomide improves the survival by 10 weeks. There is a
similar increase in survival with local delivery of BCNU,
the other currently approved chemotherapy for this
tumor [2]. The survival gains for GBM patients show
that progress can be made, but this progress has been
slow. It is not clear if large survival gains can be
achieved with the current trio of radiation, surgery and
DNA damaging chemotherapy.
Recently, GBMs have undergone a large-scale muta-
tion screen [3] and the molecular targets for this cancer
can be re-evaluated. Critical to this approach is the
identification of altered proteins or pathways that initi-
ate and/or promote tumor growth. Ideally, these mole-
cular targets are unique to the tumor cell, and therapy
specific to the alteration does not harm normal cells.
There are some very well known genes mutated in
GBM such as the tumor suppressors p53 and PTEN,
and amplification or mutation of the EGFR and
PDGFRA oncogenes. Unfortunately, molecular targeting
efforts in GBM so far have not been translated into clin-
ical success, despite some promising results of targeted
therapy in a few other cancers.
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cular targeting has not yet been successful in GBM, it is
possible that different or additional molecular targets in
combination will have better success. A recent survey of
the coding sequence of 20,661 genes in GBM genomes
has implicated many new mutated genes [3]. Similar to
other cancers there are many mutated genes in GBM
and these genes cluster into key pathways or gene
groups. This clustering occurs more than chance pre-
dicts, suggesting that these are a small number of key
cellular processes that need to be altered in the majority
GBMs. One cluster of mutated genes reported by Par-
sons et al. [3] was the ion channel genes. Of the 555
genes involved in sodium, potassium, calcium and other
ion transport, 55 mutations were detected affecting 90%
of the samples studied with at least one somatic muta-
tion. The statistical significance of this observation was
estimated to be p < 0.001 and the ion channels were
ranked as one of the top gene clusters implicated by
acquired mutations in GBM.
Ion channels form a crucial part of cellular machinery
and are responsible for transporting essential ions across
cell membranes, maintaining cell shape, cell volume and
plasma membrane potential [4-6]. Recent evidence sug-
gests a role for ion channels in cancer progression and
metastasis [7-9]. Ion channels, such as sodium channels,
potassium channels and calcium channels, have been
implicated for their role in a number of different can-
cers such as colon cancer, prostate cancer, breast cancer
and lung cancer [8,9]. For example, the up-regulation of
voltage gated sodium channels is associated with pro-
gression of breast cancer metastasis [10].
In this study, we report a correlation between ion
channel mutations and patient survival. Twenty-one
GBM patients where sodium, potassium and calcium
channel gene sequences were known [3] were analyzed
further for this study. GBM patients with a mutation in
any of the sodium channel genes had a significantly
shorter survival compared to those with wild-type
sequence. In contrast, there was no statistical survival
difference for GBM patients with either potassium or
calcium channel mutations. We extended these findings
with a preliminary in vitro laboratory investigation to
determine if known sodium channel inhibitors had an
effect on GBM cells relative to cells with a normal
genome.
Patients and Methods
Patient Characteristics
T h et w e n t y - o n ep a t i e n t si n c l u d e di nt h i ss t u d yw e r e
those analyzed for mutations in 20,661 genes in a pre-
vious study [3]. There were eight females and 13 males.
Median age of GBM patients was 45 years (median age
in males 45 years, median age in females 60 years; not
significantly different). None of the GBM patients had
received a prior chemo or a radiation therapy. One of
the 21 patients was diagnosed as a ganglioglioma patient
but was associated with a later recurrence of GBM.
Median survival of the patients was 54.9 weeks (range 2
- 215 weeks). The characteristics of patient cohort are
summarized in Table 1.
GBM Patient Samples and Genome Sequencing
The GBM sequencing results have been previously pub-
lished by Parsons et al. [3]. GBM patient tumor samples
were obtained using an IRB approved protocols.
Twenty-one GBM samples consisting of six surgically
resected patient tumors and 15 samples were passaged
in nude mice as xenografts. These 21 samples were
amplified by PCR for sequence analysis. Primer pairs
were used to amplify and sequence 175,471 coding
exons and adjacent intronic splice donor and acceptor
sequences in 21 GBM samples and one matched normal
sample as described previously [3].
Gene Selection
All the mutated genes were classified according to gene
ontology into different gene sets [3]. Ion channel classi-
fication used in this study included voltage gated ion
channels and ion co-transporters and are referred to as
channels for sake of simplicity. All the genes involved in
ion transport including, sodium channels, potassium
channels, calcium channels were selected and genes spe-
cifically associated with sodium channels, potassium
channels and calcium channels were selected individu-
ally from these sets.
Cell Culture
U-87 GBM cells were obtained from ATCC and D54
GBM cells were obtained from Duke University Medical
Center. Both U87 and D54 cells were maintained in
DMEM supplemented with 10% FBS and penicillin/
streptomycin. Non-tumor astrocytes (NTAs) consisted
of brain cortex tissue surgically resected from epilepsy
patients using an IRB approved protocol. The cortex
was cut into fine pieces using a scalpel and was cultured
for less than 8 passages in DMEM F12 cell culture med-
ium supplemented with 10% FBS and penicillin/
streptomycin.
Cell Proliferation and Drug Sensitivity Assay
The cardiac glycosides digoxin and ouabain (Sigma-
Aldrich) were dissolved in methanol and phosphate buf-
fered saline (PBS), respectively, to make a stock solution
of 25 mM. Subsequent dilutions were made from this
stock solution. Methanol and PBS were used as a vehicle
control for digoxin and ouabain respectively, during the
proliferation assay. Cell proliferation was assessed using
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Page 2 of 9Table 1 GBM patient characteristics
Tumor
ID
Patient
age
(years)
Sex Pathology Recurrent
GBM
Secondary
GBM
Prior
radiation
therapy
Prior
chemotherapy
Survival after tumor
sample obtained (Days)
Sample
type
Sodium
channel
mutations
Potassium
channel
mutations
Calcium
channel
mutations
Br02X 39 M GBM No No No No Unknown XG Yes No Yes
Br03X 44 M GBM No No No No 422 XG Yes Yes No
Br04X 45 F GBM Yes No NA NA Unknown XG No No No
Br05X 41 M GBM No No No No 563 XG No No Yes
Br06X 11 M GBM No No No No 986 XG No No No
Br07X 45 M GBM No No No No 350 XG Yes No Yes
Br08X 54 M HGG No No No No 384 XG No Yes No
Br09P 51 M GBM No No No No 588 PT Yes Yes Yes
Br10P* 30 F GBM No No No No 813 PT No No Yes
Br11P* 32 M GBM No No No No 1502 PT No Yes No
Br12P* 31 M GBM No No No No 566 PT No No Yes
Br13X 59 F GBM No No No No 174 XG Yes Yes Yes
Br14X 61 F GBM No No No No Unknown XG No Yes Yes
Br15X 61 M GBM No No No No 56 XG Yes No Yes
Br16X 63 M GBM No No No No Unknown XG Yes No Yes
Br17X 63 M GBM No No No No 964 XG No Yes Yes
Br20P 77 F GBM No No No No 122 PT Yes Yes Yes
Br23X 78 F GBM No No No No 16 XG Yes No No
Br25X 45 M GBM No No No No 48 XG Yes No No
Br26X 66 F GBM No No No No 61 XG No Yes No
Br29P 42 F HGG Yes NA NA NA Unknown PT Yes Yes No
*Patients with IDH1 mutations.
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9an alamarBlue
® assay (Invitrogen, Carlsbad, CA). U-87,
D54 and NTAs were plated (1000 cells/well) in black
clear bottom 96 well plates (Becton Dickinson, Bedford
MA) and incubated overnight. The following day, each
drug was added at its designed concentration with 20 μl
o f1 0 Xa l a m a r B l u er e a g e n t s .T h ev o l u m ei ne a c hw e l l
was made up to 200 μl with the growth medium. After
72 hours incubation, alamarBlue fluorescence was mea-
sured on a Perkin Elmer Wallac 1420 Multilabel counter
(Perkin Elmer, Turku, Finland) with a 540 nm excitation
filter and a 590 nm emission filter. Fold inhibition was
calculated by dividing the fluorescence values for control
cells (cells treated with vehicle) with fluorescence values
of cells treated with a particular concentration of cardiac
glycosides. For apoptosis analysis, both U-87 and NTAs
were plated in a six well plate (100,000 cells/well) and
incubated for 24 hours. After 24 hours, cells were trea-
ted with 500 nM of digoxin and ouabain overnight and
observed under a microscope
Statistical Analysis
GraphPad Prism 5 software was used to compute all the
survival curves. To determine the clinical outcome,
patient survival was used as a measure where survival
was defined as the time in days from first surgical resec-
tion of GBM to death. Out of 21 patient samples, survi-
val data were available for 16 different patients.
Results
Mutations in Sodium Ion Channels are Associated with
Shorter Survival in GBM Patients
Systematic analyses of functional gene groups and path-
ways from a previous study [3] identified ion channel
genes that transport sodium, potassium or calcium ions
as one of the gene groups most frequently mutated in
GBM. The sodium, potassium and calcium ion transport
gene groups were each evaluated to determine if muta-
tions in these gene groups altered average patient survi-
val. Nineteen of the 21 patients (90%) showed at least
one mutation in sodium, potassium or calcium channels
taken together. Fourteen sodium channel genes (Table 2),
13 potassium channel genes (Table 3) and 18 calcium
channel genes (Table 4) had somatic mutations. None of
the mutations were found in more than one patient except
for SCN9A, CACNA1H, and TRPV5 where each gene was
mutated in two patients. Interestingly, all the samples with
IDH1 mutations did not have any sodium channel
mutations. A comprehensive list of genes was divided into
individual lists of genes that were associated with
sodium channels, potassium channels or calcium channels
(Tables 2, 3 and 4). For example, patients were classified
into the sodium channel mutation group if they had a
mutation in at least one sodium channel gene (listed in
Table 2). If there were no mutations in any sodium chan-
nels, the patients were grouped into a sodium channel
‘unmutated’ group. Patients were grouped in a similar way
for potassium channels and calcium channels.
To determine the role of individual ion channels in
GBM patients, survival of GBM patients was compared
using Kaplan Meier analyses. GBM patients with sodium
channel mutations showed a significantly shorter survi-
val (p = 0.0079) compared to patients with unmutated
sodium channels. Median survival of GBM patients with
mutated sodium channels was 148 days compared to
689 days in patients with no sodium channel mutations
(Figure 1A). A similar comparison in GBM patients with
Table 2 Sodium channel mutations
Gene Transcript Accession Tumor Nucleotide (genomic) Nucleotide (cDNA) Amino acid (protein) Mutation Type
ATP12A NM_001676 Br13X g.chr13:24178566C>G c.2134C>G p.Q712E Missense
SCN1B CCDS12441.1 BR02X g.chr19:40213563C>T UTR-2C>T 5’UTR 5’UTR
SCN3A NM_006922 Br03x g.chr2:165772558G>A c.5612G>A p.R1871 Q Missense
SCN3B CCDS8442. 1 Br16X g.chr11:123018465_12301 8464delCT c.344_345del CT fs INDEL
SCN5A NM_000335 Br20P g.chr3:38579032G>T c.3838G>T p.V1280 F Missense
SCN9A NM_002977 Br9PT g.chr2:166987822G>A c.583G>A p.V195I Missense
SCN9A NM_002977 Br07X g.chr2:166881761C>T c.4862C>T p.T1621 M Missense
SLC11A1 CCDS2415. 1 Br25X g.chr2:219077407G>A c.520G>A p.V174I Missense
SLC1A2 NM_004171 Br03X g.chr11:35239082_352390 81delCT c.1660_1661 delCT fs INDEL
SLC5A7 CCDS2074. 1 Br15X g.chr2:108067164C>A c.263C>A p.P88Q Missense
SLC8A1 CCDS1806. 1 Br07X g.chr2:40568624C>G c.448C>G p.L150V Missense
SLC9A1 CCDS295.1 Br07X g.chr1:27120218C>T c.1006C>T p.L336F Missense
SLC9A2 CCDS2062. 1 Br23X g.chr2:102732730G>A c.479G>A p.R160H Missense
SLC9A4 NM_001011 552 Br9PT g.chr2:102583058G>A c.1201G>A p.V401I Missense
TRPM5 NM_014555 Br29P g.chr11:2382782G>A c.3459G>A p.W1153 X Missense
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Page 4 of 9mutated and unmutated potassium channels (Figure 1B),
and mutated and unmutated calcium channels (Figure
1C) showed no significant difference in survival. These
observations suggest that survival difference seen in
GBM patients with mutated and unmutated sodium
channels are not random.
GBM patients with PTEN mutations are associated
with shorter survival [11]. Therefore, to rule out the
effect of PTEN mutation on the survival curves with
mutated and unmutated sodium channels, we excluded
the patients with PTEN mutations. In spite of the exclu-
sion of patients with PTEN mutation, GBM patients with
sodium channel mutations were associated with signifi-
cantly shorter survival (Figure 1D). Median survival of
patients with sodium channel mutations was 122 days
compared to 566 days in patients with no mutations.
Table 4 Calcium channel mutations
Gene Transcript Accession Tumor Nucleotide (genomic)* Nucleotide (cDNA) Amino acid (protein) Mutation Type
ATP2B1 CCDS9035.1 Br12P g.chr12:88531401T>A c.502T>A p.L168I Missense
CACNA1A NM_000068 Br15X g.chr19:13184518C>T c.5980C>T p.P1994S Missense
CACNA1C NM_000719 Br17X g.chr12:2094747C>A c.146C>A p.A49D Missense
CACNA1H NM_021098 Br15X g.chr16:1199144C>T c.3475C>T p.Q1159X Missense
CACNA1H NM_021098 Br05X g.chr16:1201735G>A c.4495G>A p.V1499M Missense
CACNA2D3 NM_018398 Br07X g.chr3:54905889G>A c.2320G>A p.A774T Missense
CHRNA3 CCDS10305.1 Br14X g.chr15:76681620T>C c.419T>C p.L140S Missense
CHRNA9 CCDS3459.1 Br15X g.chr4:40197220C>T c.1195C>T p.R399C Missense
GRIN2B CCDS8662.1 Br13X g.chr12:13608123G>A c.3316G>A p.E1106K Missense
GRM1 CCDS5209.1 Br15X g.chr6:146761918C>T c.2050C>T p.R684C Missense
ITPR3 CCDS4783.1 Br16X g.chr6:33761264G>A c.5458G>A p.E1820K Missense
KIAA0703 NM_014861 Br20P g.chr16:83006699G>A IVS5+1G>A Splice Site Splice Site
NMUR1 CCDS2486.1 Br20P g.chr2:232219206C>T c.31C>T p.L11F Missense
PKD1L2 NM_182740 Br14X g.chr16:79765857G>T c.2747G>T p.G916V Missense
RYR2 NM_001035 Br10P g.chr1:233820306G>A c.256G>A p.V86M Missense
RYR2 NM_001035 Br17X g.chr1:233858930G>A c.365G>A p.R122H Missense
RYR3 NM_001036 Br9PT g.chr15:31893017C>T c.10447C>T p.R3483W Missense
SLC8A1 CCDS1806.1 Br07X g.chr2:40568624C>G c.448C>G p.L150V Missense
STIM2 CCDS3440.1 Br02X g.chr4:26686687G>T c.1544G>T p.R515L Missense
TRPV5 CCDS5875.1 Br15X g.chr7:142139519G>A c.1064G>A p.R355H Missense
TRPV5 CCDS5875.1 Br14X g.chr7:142139507G>A c.1076G>A p.R359H Missense
Table 3 Potassium channel mutations
Gene Transcript Accession Tumor Nucleotide (genomic)* Nucleotide (cDNA) Amino acid (protein) Mutation Type
ATP12A NM_001676 Br13X g.chr13:24178566C>G c.2134C>G p.Q712E Missense
GRIK4 CCDS8433.1 Br17X g.chr11:120343207G>A c.2360G>A p.G787E Missense
KCNA4 NM_002233 Br29P g.chr11:29990620C>T c.182C>T p.S61F Missense
KCNB2 CCDS6209.1 Br11P g.chr8:74011087G>A c.943G>A p.A315T Missense
KCND2 CCDS5776.1 Br03X g.chr7:119979914C>T c.1597C>T p.R533X Missense
KCNG3 CCDS1809.1 Br26X g.chr2:42631881G>A c.412G>A p.D138N Missense
KCNH1 CCDS1496.1 Br9PT g.chr1:207365704G>T c.1662G>T p.K554N Missense
KCNH5 CCDS9756.1 Br08X g.chr14:62316201C>T c.2017C>T p.R673W Missense
KCNJ15 CCDS13656.1 Br03X g.chr21:38593138G>A c.85G>A p.V29I Missense
KCNK1 CCDS1599.1 Br26X g.chr1:230109198G>A c.478G>A p.V160I Missense
LRRC4B ENST00000253728 Br03X g.chr19:55713328C>T c.809C>T p.T270I Missense
REN NM_000537 Br20P g.chr1:200862821G>A c.226G>A p.V76M Missense
SLC12A5 CCDS13391.1 Br14X g.chr20:44097883G>A c.340G>A p.V114I Missense
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Glioblastoma Cells
Because sodium channel mutations had a substantial
effect on GBM patient survival, targeting sodium chan-
nels may be an effective way to counter GBM cell
growth. We started our study with sodium channel inhi-
bitors with previous clinical use. Based on information
in the literature, and a larger screen of libraries of
approved drugs (data not shown), we selected two car-
diac glycosides, digoxin (FDA approved) and ouabain, to
test on GBM cells. Our reasoning for choosing cardiac
glycosides was based on two main previously reported
findings. First, the anti-proliferative or anticancer effect
of cardiac glycosides is well documented [12-14] and
second; cardiac glycosides may be neuroprotective [15]
and thus, might be used safely in the central nervous
system.
T h ee f f e c to fo u a b a i na n dd i g o x i no np r o l i f e r a t i o no f
U-87 and D54 GBM cells and NTAs was tested first,
using an alamarBlue based assay. Cells were treated at
different concentrations ranging from 10 nM to 50 μM
in a 96 well plate. After 72 hours, both digoxin and oua-
bain showed preferential anti-proliferation and toxicity
against U-87 and D54 GBM cells compared to the
NTAs (Figure 2A and 2B). In addition, comparison of
growth curves of U-87 and NTAs treated with 500 nM
digoxin and ouabain demonstrated a preferential inhibi-
tion of U-87 GBM cells over NTAs (Figure 2C and 2D).
Figure 1 Sodium ion channel mutations predict shorter survival in GBM. A: Survival of GBM patients was compared in patients with
mutated and unmutated sodium channels using log rank test. Analysis revealed that GBM patients with sodium channel mutations (n = 8) had
a significantly shorter survival (p = 0.0079) compared to patients with no sodium channel mutations (n = 8). B: GBM patient survival was
compared on the basis of potassium channel mutations. There was no significant difference in median survival of patients with (n = 8) and
without (n = 8) potassium channel mutations. C: Analysis of calcium channels also failed to show any significant difference in survival of GBM
patients when compared on the basis of presence (n = 9) or absence (n = 7) of calcium channel mutations. D: In order to exclude the effect of
PTEN mutations on survival of GBM patients with sodium channel mutations, patients with PTEN mutation were excluded from the analysis and
the survival curves compared on the basis of presence or absence of sodium channel mutations. Exclusion of PTEN did not have any effect and
GBM patients with sodium channel mutations (n = 5) showed a significantly shorter survival (p = 0.048) compared to patients with no sodium
channel mutations (n = 7).
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tially targeted by an alternative technique, U-87 cells and
NTAs treated with 500 nM of digoxin and ouabain over-
night and were observed under a light microscope next
morning. Figure 3 demonstrates that U-87 GBM cells
treated with digoxin and ouabain detach and showed an
apoptotic phenotype, whereas NTAs remained adherent
and did not show an apoptotic phenotype, confirming
the preferential cytotoxicity of cardiac glycosides.
Discussion
In the GBM patients studied those with mutations in the
sodium ion channel genes had a significantly shorter sur-
vival compared to patients without a mutation. In com-
parison, similar analyses of mutations in potassium
channels and calcium channels showed no statistical sur-
vival differences. One biological possible explanation for
this observation is that sodium channel mutations pro-
mote GBM tumor growth and/or invasion, thereby
decreasing survival, whereas other non-sodium ion chan-
nel mutations do not function to alter invasion. This is
the first report suggesting a possible role of ion channel
mutations in GBM prognosis. Nineteen out of 21 (90%)
patient samples showed at least one mutation in sodium,
potassium or calcium channels. It will be important to
see if this observation can be reproduced in larger studies
and/or other patient populations. Furthermore, it was
found that patients with no sodium channel mutations
were younger (median age 43 years) compared to patients
with mutated sodium channel mutations (median age
51 years), although the difference did not turn out to be
statistically significant (p = 0.117).
Recently, IDH1 mutations have been identified to be
associated with a specific subgroup of GBM patients
Figure 2 Cardiac glycosides preferentially target GBM cells over non tumor astrocytes (NTAs): U-87, D54 GBM cells and NTA cells when
treated with different concentrations of cardiac glycosides demonstrated a significantly higher cytotoxicity (p < 0.05) against GBM cells at
concentrations ranging from 50 μM to 500 nM. At concentrations of 100 nM and below there was no significant cytotoxic effect. A: Bar graph
demonstrating preferential cytotoxicity of Digoxin against U-87 and D54 GBM cells B: Bar graph demonstrating preferential cytotoxicity of Ouabain
against U-87 and D54 GBM cells. C and D: Growth curves of U-87 GBM and NTAs were plotted for four days using an alamarBlue based assay
demonstrate preferential inhibition of U-87 GBM cells compared to NTAs when treated with 500 nM of Digoxin (2C) and Ouabain (2D).
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Page 7 of 9who are younger and have a better prognosis [3,16].
I n t e r e s t i n g l y ,w ef o u n dt h a ta l lt h ep a t i e n t sw i t hI D H 1
mutations were a part of sodium channel unmutated
group. However it is not known whether this association
is significant because of the small sample size. It also
raises the question whether IDH1 mutations would con-
tribute to improved survival in patients with unmutated
sodium channels. Analysis of survival data after exclud-
ing IDH1 mutated patients revealed that median survival
in patients with sodium channel mutations was 148 days
compared to 563 days in sodium channel unmutated
patients in accordance with our earlier observations,
however the p value dropped to 0.06 (data not shown).
These observations warrant a larger and more in depth
study to investigate whether there is an association
between IDH1 mutation and GBM patients with unmu-
tated sodium channels and whether the improved survi-
val seen in GBM patients with unmutated sodium
channels is independent of IDH1 mutation status.
Ion channel genes were mutated at a higher frequency
compared to other genes (p < 0.001). Moreover, individual
groups of genes consisting of calcium ion transport (p <
0.001), sodium ion transport (p < 0.005) and potassium
ion transport (p = 0.037) showed a significantly higher fre-
quency of mutation [3]. Most of the ion channel genes
were mutated only once except for SCN9A, CACNA1H
and TRPV5 which were each mutated twice in the set of
21 patients. Since no gene was mutated more than twice
in this set and there are many possible ion channels with
mutations, this indicates a low mutation rate for each indi-
vidual gene, despite the group being highly mutated. Sub-
set classes of the ion channels, such as SCN or SLC (both
sodium channels) or KCN (potassium channels), were also
enriched for mutations [3]. These observations suggests
that mutations in a gene family or molecular pathway of
similar function when considered in combination may be
more informative than a single gene, when evaluating
tumor growth and selecting molecular targets.
In this report, we have used the mutation status of
sodium channels as a variable for comparing patient
survival. However, which mutations are relevant to
GBM biology and how they alter the clinical course of
GBM remains unknown. One interpretation of our data
is that sodium channel inhibition slows tumor cell
growth, suggesting that sodium channel mutations are
activating, or activate some mechanism responsible for
poor prognosis. However, there is no evidence at the
molecular level as to how these mutations might work.
Further in depth molecular physiological studies to
determine the direct effect of the mutations on mem-
brane potential and polarization/depolarization and cell
signaling of the tumor cells would be an option to study
this question.
Sodium, potassium and calcium channels form an
intricate network that maintains ionic balance in the cell
and mutation in any one of the ion channels could alter
many cellular functions. One hypothesis is that ion
channel mutations are partially responsible for the
increased motility of GBM cells. Voltage gated sodium
channels have already been implicated for their role in
enhancing the invasiveness of breast cancer and prostate
cancer [10,17-19]. Higher expression of SCN5A has
been associated with higher metastatic potential. It has
also been reported that EGF may increase metastatic
potential of prostate cancer by up regulation of SCN9A
[19]. Although, our data does not describe expression
levels of sodium channels, there is a possibility that the
mutations in SCN5A and SCN9A may cause an increase
in the activity of sodium channels thereby increasing the
metastatic potential of GBM and decreasing survival of
the patients.
Ion channels might be investigated as a pharmacologi-
cal target for GBM patient therapy. Our data demon-
strates that ion channel inhibitors, cardiac glycosides in
this case can preferentially inhibits GBM cells over non-
tumor astrocytes (NTAs) when tested in vitro.T h e r ei s
no evidence yet that cardiac glycosides molecularly
Figure 3 Light microscope pictures depicting apoptotic
phenotype/dead U-87 GBM cells after an overnight treatment
with ouabain and digoxin. Non-tumor astrocytes remain
unaffected for most part, although they demonstrated delayed
(after 36 hrs) apoptotic phenotype.
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Page 8 of 9interact directly with any of the mutated sodium chan-
nel (shown in Table 2). Nevertheless, preferential target-
ing of GBM cells by cardiac glycosides suggests that ion
channels can be targeted and should be evaluated as a
therapeutic drug target for treating GBM in the future.
Attempts have been made to treat GBMs with cardiac
glycosides with modified structures that reduce their
cardio-toxicity and increase anti-proliferative capability
[20]. Similarly, targeting of a1 subunit of the sodium
pump using the siRNA inhibited growth and migration
of lung cancer cells [21]. Voltage gated sodium channels
have also been targeted in prostate cancer cells with
encouraging results [22].
Conclusion
In summary, we have shown that mutations in sodium
channels are associated with an aggressive form of
GBM. We also show in vitro growth inhibition by ion
channel inhibitors, suggesting that GBM might be tar-
geted using ion channel inhibitors. These observations
from different lines of investigation hint that sodium ion
channels should be investigated further as a molecular
therapeutic target in GBM.
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